Table 1.
Patient demographics and pathologic characteristics
| FTLD group | (N) | Sex | (N) | Education (years) | Age at death (years) | Disease Duration (years) | Post-mortem Interval (hours) | Mutation status | (N) | Primary Neuro-pathologic Diagnoses | (N) | Co-morbid pathologies | Clinical diagnoses | (N) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Secondary Neuro-pathologic Diagnoses | (N) | AD Neuro-pathologic Change | (N) | ||||||||||||||
| tau | 73 | Female | 33 | 15.3 (2.6) | 71 (11.1) | 7.9 (3.8) | 11.7 (7.2) | MAPT | 6 | CBD | 14 | ARTAG | 28 | Not | 39 | bvFTD | 28 |
| Male | 40 | [10–20] | [31–94] | [3–20] | [1.5–41] | PiD | 14 | HS | 1 | Low | 26 | CBS | 5 | ||||
| * | * | PSP | 36 | LBD-A | 1 | Int | 4 | PPA | 16 | ||||||||
| TauU | 9 | LBD-B | 8 | High | 2 | PSPS | 24 | ||||||||||
| N/A | 2 | ||||||||||||||||
| TDP | 97 | Female | 41 | 15.6 (3.0) | 66 (9.7) | 6 (3.6) | 11.8 (6.8) | C9orf72 | 21 | ALS | 34 | ARTAG | 16 | Not | 25 | ALS | 28 |
| Male | 56 | [10–22] | [41–96] | [1–19] | [0–30] | GBE1 | 1 | TDP-A | 25 | CVD | 2 | Low | 41 | bvFTD | 50 | ||
| GRN | 14 | TDP-B | 17 | CTE | 1 | Int | 8 | CBS | 2 | ||||||||
| TBK1 | 2 | TDP-C | 16 | HS | 7 | High | 2 | PPA | 17 | ||||||||
| TDP-E | 5 | LBD-A | 5 | N/A | 0 | ||||||||||||
| LBD-B | 7 | ||||||||||||||||
| LBD-L | 3 | ||||||||||||||||
| PART | 21 | ||||||||||||||||
| TauU | 3 | ||||||||||||||||